BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

VERTEX PHARMACEUTICALS — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Report

VERTEX PHARMACEUTICALS

via SALT POINT STRATEGIES

3rd Quarter (July 1 - Sep 30) · 2025Posted Oct 20, 2025Filing document ↗LDA record ↗

Income$30Kfee reported

Client

Name: VERTEX PHARMACEUTICALS
Description: Biopharmaceutical company.
Location: Massachusetts · United States of America

Registrant

Firm: SALT POINT STRATEGIES
Description: Strategic consulting
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Pharmacy
Non-opioid pain relief and drug pipeline issues.
LobbyistsADAM BUCKALEW
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.